Research programme: TDP-43 positron emission tomography tracers - AC Immune/Biogen
Alternative Names: TDP-43-PET imaging agents; TDP-43-PET tracer programLatest Information Update: 27 Oct 2025
At a glance
- Originator AC Immune; Biogen
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurodegenerative disorders
Most Recent Events
- 27 Oct 2025 TDP-43 positron emission tomography tracers are still in Preclinical trials in Neurodegenerative disorders (Diagnosis) in Switzerland (AC Immune pipeline, October 2025)
- 14 Mar 2024 AC immune plans a phase I trial in second half of 2024
- 04 Aug 2023 Preclinical trials in Neurodegenerative disorders (Diagnosis) in Switzerland (unspecified route)